Top View
- Nintedanib for Previously Treated Locally Advanced, Metastatic, Or Locally Recurrent Non-Small-Cell Lung Cancer
- Erlotinib Is Effective in Pancreatic Cancer with Epidermal Growth Factor Receptor Mutations: a Randomized, Open-Label, Prospective Trial
- Phase II Trial of Dasatinib for Patients with Acquired Resistance To
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits
- Combining Erlotinib and Cetuximab Is
- HAZARDOUS DRUGS (Non-Chemotherapy) – ADMINISTRATION and PRECAUTIONS
- Genetic Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer
- Tarceva, INN-Erlotinib
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Negative HNSCC – Alteration of EGFR and VEGFR-2 Expression in Vitro
- Nintedanib for Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Single Technology Appraisal: Evidence Review Group Report Page 1 of 139
- Readministration of EGFR Tyrosine Kinase Inhibitor in Non
- Efficacy of Erlotinib and Imatinib in a Patient with a Rectal Gastrointestinal Stromal Tumor and Synchronous Pulmonary Adenocarcinoma : a Case Report
- Renal Cell Carcinoma Treatment Regimens
- Reimbursement Criteria for Frequently Requested Drugs
- Tarceva (Erlotinib) Label
- Substrate-Dependent Modulation of the Catalytic Activity of CYP3A by Erlotinib
- Second-Line Treatment for Advanced NSCLC Without Actionable Mutations: Is Immunotherapy the ‘Panacea’ for All Patients? Alessandro Morabito
- Colorectal Cancer Growth Retardation Through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
- An Open-Label, Randomized Phase 3 Efficacy Study of ASP8273 Vs
- Enobosarm (Ostarine) for Cachexia in Patients with Advanced Non-Small Cell Lung Cancer – First Line
- Oncology Agents Policy #: Rx.01.67
- A Comparison Between First-, Second- and Third-Generation Epidermal
- Overview of Molecular Testing in Non-Small-Cell Lung Cancer
- Nilotinib Shows Prolonged Intracellular Accumulation Upon Pulse-Exposure: a Novel Mechanism for Induction of Apoptosis in CML Cells
- Erlotinib Versus Gefitinib for Brain Metastases in Asian Patients With
- HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
- Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
- Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
- Comparative Analysis of Drug Response and Gene Profiling Of
- Tyrosine Kinase Inhibition in HPV-Related Squamous Cell
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Oral Targeted Therapy for Cancer
- Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
- Clinical Trials Appendix Q1 2019 Results Update
- The HDAC Inhibitor, MPT0E028, Enhances Erlotinib-Induced Cell Death in EGFR-TKI-Resistant NSCLC Cells
- Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin
- Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer
- An Open-Label Multi-Center Study of Erlotinib (Tarceva®) As First Line Therapy Until and Beyond RECIST Progression in NSCLC Patients Who Harbor EGFR Mutations
- 1 Hope in a Bottle for NSCLC: ERLOTINIB Katherine Bliven, Pharmd Candidate 20151, Kristy Brittain, Pharmd, BCPS, CDE1,2 1 South
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib
- Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
- Antimalarial Activity of Kinase Inhibitor, Nilotinib, in Vitro and in Vivo
- Comparative Effect of Tyrosine Kinase Inhibitors in Human Cancer Cell Lines
- Maximizing the Clinical Relevance of Nonclinical Oncology Studies Mary E
- A Phase 2 SWOG Study of Sorafenib and Erlotinib in Patients with Advanced Gallbladder Carcinoma Or Cholangiocarcinoma
- Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin B1/Src/Akt-Driven Bypass Signaling
- Structural Basis for the Altered Drug Sensitivities of Non-Small Cell Lung Cancer-Associated Mutants of Human Epidermal Growth Factor Receptor
- Thyroid Effects of Tyrosine Kinase Inhibitors
- Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2